A patient with acute myeloid leukemia received a bone marrow transplant from a deceased donor, achieved engraftment, and has ...

Investigators assessed whether intravesical BCG is necessary for patients with high-grade T1 nonmuscle-invasive bladder cancer who have unremarkable histology on the second transurethral resection.

Medicaid expansion was associated with a slower decrease in receipt of guideline-concordant treatment, reduced delays in treatment initiation, and improved 2-year survival, according to researchers.

With a median follow-up duration of 55 months, the tandem ASCT group had a median PFS of 42 months compared with 62 months in the single ASCT group. In a real-world study involving patients with ...

Most people erroneously think pancreatic cancer occurs only in older people and that they cannot alter risk. HealthDay News — Most people continue to believe that pancreatic cancer affects only the ...

Lack of insurance accounts for significant proportion of racial, ethnic disparities in stage III to IV diagnoses across range of cancers.

In this study, the CR rate with atezolizumab was 28.6, and at 12 months, the PFS was 42.9% and OS was 64.3%. These results suggest “that this chemotherapy-free regimen could become a new first-line ...

The 5-year disease-free survival rate was 63.3% for patients with microsatellite instability and 41.4% for patients with microsatellite-stable disease. Microsatellite instability (MSI) is a “striking” ...

Physical function assessments with TUG and SPPB did not identify a decline in function among patients with CRPC receiving darolutamide over 24 weeks.

Chemotherapy was associated with short-term cognitive dysfunction after treatment completion among patients with breast cancer. These findings were published in The Oncologist. Chemotherapy-induced ...

Patients with abnormal numbers of CD3 + T cells had considerably higher mortality and recurrence rates. The immune system and especially the B cells of patients with acute lymphoblastic leukemia (ALL) ...

Researchers estimated worldwide epidemiological trends in melanoma from 1990 to 2021, including incidence, mortality, and disability adjusted life years.